ArticleDermatology and therapy2026
Real-World Broadband Light Treatment Strategies and Early Treatment Response in Facial Vascular Lesions: A Retrospective Observational Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBroadband light (BBL) therapy is increasingly used for the treatment of facial vascular lesions; however, real-world data regarding individualized treatment strategies and factors associated with treatment outcomes remain limited. This study aimed to evaluate real-world BBL treatment approaches for facial vascular lesions and to investigate the relationship between early treatment response and overall treatment outcomes.
methodsThis retrospective real-world study included 111 patients with facial vascular lesions treated with BBL therapy between March 2023 and September 2025 at a tertiary dermatology center. Diagnoses included rosacea (n = 59), facial telangiectasia (n = 37), hemangiomas (n = 11), and port-wine stains (n = 4). Treatment characteristics, clinical outcomes, and adverse events were analyzed. Clinical efficacy was assessed by two blinded dermatologists using standardized photographs. First-session and overall treatment responses were categorized according to the degree of clinical improvement. Associations between early and overall treatment responses were evaluated using Spearman's rank correlation analysis.
resultsTreatment outcomes differed significantly among diagnostic groups (p < 0.001). Rosacea and hemangiomas demonstrated the most favorable responses, whereas facial telangiectasia showed comparatively lower response rates. A moderate positive correlation was observed between first-session and overall treatment responses (ρ = 0.533, p < 0.001). All patients who were early responders (≥ 50% improvement after the first session) subsequently achieved overall treatment success, compared with 46.5% of patients who were non-early responders (p < 0.001). Patients who were early responders also required fewer treatment sessions (p < 0.001). Within major diagnostic groups, no significant associations were identified between specific treatment parameter combinations and overall treatment responses, whereas treatment session number correlated positively with treatment outcomes. Localized microcrusting occurred in 17.1% of patients and resolved without sequelae; no serious adverse events were observed.
conclusionsThe observed treatment patterns and outcomes suggest that BBL therapy may be integrated into routine management of facial vascular lesions. Early treatment response was associated with subsequent treatment outcomes and treatment burden, and may provide clinically useful information for individualized treatment planning and patient counseling.
Indexed as
Identifiers
42799822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.